中文

菲利华 Revenue Breakdown

Period 2026-06-30 ・ Reported 2026-08-21

菲利华 reported revenue of ¥1.31B for the period ended 2026-06-30, +44.1% year on year. Net income was ¥0.31B, a 23.6% net margin on a 50.1% gross margin. The largest revenue line is 石英玻璃材料 at 56% of the total. Free cash flow for the period was ¥-0.11B.

ItemAmountY/Y
Revenue¥1.31B+44.1%
Gross profit¥0.66B
Operating income¥0.37B
Net income¥0.31B+47.8%
Gross margin50.1%Net margin 23.6%
Revenue Q/Q+10.4%

Revenue Segments

SegmentRevenueShare
石英玻璃材料¥0.74B56.5%
石英玻璃制品¥0.56B42.6%
其他(补充)¥0.01B1.0%

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥0.65B49.9%
R&D¥0.16B12.3%
SG&A¥0.12B9.5%
Tax & other¥0.06B4.4%

Balance sheet & cash flow

ItemAmount
Total assets¥8.17B
Total liabilities¥1.71B
Shareholders' equity¥6.46B
Equity / assets79.0%
Operating cash flow¥0.12B
Capital expenditure¥0.22B
Free cash flow¥-0.11B
Cash conversion (OCF / net income)44%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

ST迪瑞天和防务飞凯材料天利科技劲拓股份花园生物宝色股份汉宇集团博济医药科隆股份九强生物凯发电气

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies